Baseline erythropoietin level predicts Luspatercept response in Chinese patients with myelodysplastic syndrome: a propensity score-matched analysis
Background: Luspatercept is a novel erythroid maturation agent approved for treating transfusion-dependent anemia in myelodysplastic syndrome (MDS). However, predictive biomarkers and real-world data in Asian populations remain limited. Methods: We conducted a retrospective cohort study of 66 MDS pa...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048925000342 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|